p53 and the malignant progression of Barrett's esophagus

Authors

  • Elettra Merola,

    1. Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, Center for Biotechnology, Philadelphia
    Search for more papers by this author
  • Pier Paolo Claudio,

    1. Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, Center for Biotechnology, Philadelphia
    Search for more papers by this author
  • Antonio Giordano

    Corresponding author
    1. Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, Center for Biotechnology, Philadelphia
    • Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Bio Life Sciences Building, Suite 333, 1900 North 12th Street, Philadelphia, PA 19122-6099.
    Search for more papers by this author

Abstract

Barrett's esophagus (BE) is a metaplastic disorder in which specialized columnar epithelium replaces healthy squamous epithelium (intestinal metaplasia). Even though its pathophysiology and the steps of its neoplastic progression are not completely understood, BE can be considered as a complication of gastroesophageal reflux disease (GERD). Given that esophageal adenocarcinoma, which is continually increasing in the Western world, still has a poor prognosis and suffers from late diagnosis, and because BE is a precancerous lesion, there is a strong need for good molecular markers of malignant progression in Barrett's metaplasia (BM). The aim of this review is to examine the published data regarding the role that assessment of p53 may play in the management of BE, trying to understand if it may be a useful marker to early diagnose BE malignant transformation. © 2005 Wiley-Liss, Inc.

Ancillary